• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. Apr 2002; 61(4): 298–304.
PMCID: PMC1754073

Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors

Full Text

The Full Text of this article is available as a PDF (167K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385–390. [PubMed]
  • Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000 Jun;59(6):428–433. [PMC free article] [PubMed]
  • Biondi Oriente C, Scarpa R, Pucino A, Oriente P. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Derm Venereol Suppl (Stockh) 1989;146:69–71. [PubMed]
  • Espinoza LR, Cuéllar ML, Silveira LH. Psoriatic arthritis. Curr Opin Rheumatol. 1992 Aug;4(4):470–478. [PubMed]
  • Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 2000 May;27(5):1247–1250. [PubMed]
  • Scarpa R, Oriente P, Pucino A, Torella M, Vignone L, Riccio A, Biondi Oriente C. Psoriatic arthritis in psoriatic patients. Br J Rheumatol. 1984 Nov;23(4):246–250. [PubMed]
  • Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990 Jun;17(6):809–812. [PubMed]
  • Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol. 1991 Aug;30(4):245–250. [PubMed]
  • Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol. 1995 Apr;22(4):675–679. [PubMed]
  • Espinoza LR, van Solingen R, Cuellar ML, Angulo J. Insights into the pathogenesis of psoriasis and psoriatic arthritis. Am J Med Sci. 1998 Oct;316(4):271–276. [PubMed]
  • Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol. 1999 Apr;140 (Suppl 54):1–7. [PubMed]
  • Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994 Apr;96(1):146–151. [PMC free article] [PubMed]
  • Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol. 1999;455:221–225. [PubMed]
  • Gladman DD. Psoriatic arthritis. Rheum Dis Clin North Am. 1998 Nov;24(4):829–x. [PubMed]
  • Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55–78. [PubMed]
  • Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol. 1999 Aug;26(8):1752–1756. [PubMed]
  • McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum. 1999 Jun;42(6):1080–1086. [PubMed]
  • Fournié B, Crognier L, Arnaud C, Zabraniecki L, Lascaux-Lefebvre V, Marc V, Ginesty E, Andrieu V, Dromer C, Fournié A. Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients. Rev Rhum Engl Ed. 1999 Oct;66(10):446–456. [PubMed]
  • Marsal S, Armadans-Gil L, Martínez M, Gallardo D, Ribera A, Lience E. Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology (Oxford) 1999 Apr;38(4):332–337. [PubMed]
  • Rahman P, Schentag CT, Beaton M, Gladman DD. Comparison of clinical and immunogenetic features in familial versus sporadic psoriatic arthritis. Clin Exp Rheumatol. 2000 Jan-Feb;18(1):7–12. [PubMed]
  • Gladman DD, Cheung C, Ng CM, Wade JA. HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol. 1999 Mar;60(3):259–261. [PubMed]
  • Hamilton ML, Gladman DD, Shore A, Laxer RM, Silverman ED. Juvenile psoriatic arthritis and HLA antigens. Ann Rheum Dis. 1990 Sep;49(9):694–697. [PMC free article] [PubMed]
  • FitzGerald O. Advances in understanding and novel therapeutic targets in inflammatory arthritis. Ir J Med Sci. 1995 Jan;164(1):4–11. [PubMed]
  • Costello P, Bresnihan B, O'Farrelly C, FitzGerald O. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol. 1999 May;26(5):1117–1124. [PubMed]
  • Partsch G, Steiner G, Leeb BF, Dunky A, Bröll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997 Mar;24(3):518–523. [PubMed]
  • Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. 2000 Jun;43(6):1244–1256. [PubMed]
  • Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998 Aug;25(8):1544–1552. [PubMed]
  • Partsch G, Wagner E, Leeb BF, Bröll H, Dunky A, Smolen JS. T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis. 1998 Nov;57(11):691–693. [PMC free article] [PubMed]
  • Pringle F. A multidisciplinary approach to psoriatic arthropathy. Community Nurse. 1999 May;5(4):21–22. [PubMed]
  • Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, Cathcart ES, Samuelson CO, Jr, Solsky MA, Kaplan SB, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984 Apr;27(4):376–381. [PubMed]
  • Palit J, Hill J, Capell HA, Carey J, Daunt SO, Cawley MI, Bird HA, Nuki G. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol. 1990 Aug;29(4):280–283. [PubMed]
  • Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Bacon PA. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol. 1990 Feb;29(1):46–49. [PubMed]
  • Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, Budiman-Mak E, Blackburn WD, Vasey FB, Mahowald ML, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996 Dec;39(12):2013–2020. [PubMed]
  • Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, Rocher LL, Wheeler S, Hamilton TA, Parish TG, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med. 1991 Jan 31;324(5):277–284. [PubMed]
  • Hacker SM, Ramos-Caro FA, Ford MJ, Flowers FP. Azathioprine: a forgotten alternative for treatment of severe psoriasis. Int J Dermatol. 1992 Dec;31(12):873–874. [PubMed]
  • Le Quintrec JL, Menkès CJ, Amor B. Rhumatisme psoriasique grave. Traitement par azathioprine. A propos de onze cas. Rev Rhum Mal Osteoartic. 1990 Nov;57(11):815–819. [PubMed]
  • Sayers ME, Mazanec DJ. Use of antimalarial drugs for the treatment of psoriatic arthritis. Am J Med. 1992 Oct;93(4):474–475. [PubMed]
  • Luzar MJ. Hydroxychloroquine in psoriatic arthropathy: exacerbations of psoriatic skin lesions. J Rheumatol. 1982 May-Jun;9(3):462–464. [PubMed]
  • Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol. 1995 Feb;22(2):241–245. [PubMed]
  • Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol Suppl. 1999 May;57:16–21. [PubMed]
  • Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996 Jun 27;334(26):1717–1725. [PubMed]
  • Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, Charrier K, Morrissey PJ, Ware CB, Mohler KM. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol. 1998 Jan 15;160(2):943–952. [PubMed]
  • Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, Brennan FM, Maini RN, Wallach D, Feldmann M. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum. 1992 Oct;35(10):1160–1169. [PubMed]
  • Roux-Lombard P, Punzi L, Hasler F, Bas S, Todesco S, Gallati H, Guerne PA, Dayer JM. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum. 1993 Apr;36(4):485–489. [PubMed]
  • Partsch G, Wagner E, Leeb BF, Dunky A, Steiner G, Smolen JS. Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol. 1998 Jan;25(1):105–110. [PubMed]
  • Tracey KJ, Vlassara H, Cerami A. Cachectin/tumour necrosis factor. Lancet. 1989 May 20;1(8647):1122–1126. [PubMed]
  • Herrera-Garza EH, Stetson SJ, Cubillos-Garzon A, Vooletich MT, Farmer JA, Torre-Amione G. Tumor necrosis factor-alpha: a mediator of disease progression in the failing human heart. Chest. 1999 Apr;115(4):1170–1174. [PubMed]
  • Husby G, Williams RC., Jr Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun. 1988 Aug;1(4):363–371. [PubMed]
  • Deleuran BW, Chu CQ, Field M, Brennan FM, Katsikis P, Feldmann M, Maini RN. Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol. 1992 Dec;31(12):801–809. [PubMed]
  • Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986 Aug 7;322(6079):547–549. [PubMed]
  • Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986 Feb 6;319(6053):516–518. [PubMed]
  • Shinmei M, Masuda K, Kikuchi T, Shimomura Y. The role of cytokines in chondrocyte mediated cartilage degradation. J Rheumatol Suppl. 1989 Aug;18:32–34. [PubMed]
  • Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med. 1985 Dec 1;162(6):2163–2168. [PMC free article] [PubMed]
  • Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol Suppl. 1999 May;57:7–15. [PubMed]
  • Mouser JF, Hyams JS. Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin Ther. 1999 Jun;21(6):932–931. [PubMed]
  • Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244. [PubMed]
  • Sheehan KC, Pinckard JK, Arthur CD, Dehner LP, Goeddel DV, Schreiber RD. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J Exp Med. 1995 Feb 1;181(2):607–617. [PMC free article] [PubMed]
  • Tartaglia LA, Goeddel DV, Reynolds C, Figari IS, Weber RF, Fendly BM, Palladino MA., Jr Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol. 1993 Nov 1;151(9):4637–4641. [PubMed]
  • Baseta JG, Stutman O. TNF regulates thymocyte production by apoptosis and proliferation of the triple negative (CD3-CD4-CD8-) subset. J Immunol. 2000 Nov 15;165(10):5621–5630. [PubMed]
  • Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995 Sep 28;377(6547):348–351. [PubMed]

Figures and Tables

Figure 1
Distal interphalangeal joint involvement in the fingers of a patient with arthritis mutilans, a severe form of psoriatic arthritis.
Figure 2
Tumour necrosis factor (TNF) expression in a synovial membrane section from an affected joint of a patient with a severe form of psoriatic arthritis, arthritis mutilans (original magnification x600). The section was stained with a monoclonal antibody ...
Figure 3
Neutralisation of TNF by soluble TNF receptors (sTNFR) or anti-TNF monoclonal antibody (mAb) prevents TNF binding to either the p55 or the p75 receptors.47, 64–67
Figure 4
Clinical response as assessed by Psoriatic Arthritis Response Criteria (PsARC) in patients with PsA treated with etanercept or placebo. Adapted from Mease 20001 with permission.
Figure 5
Clinical response as assessed by American College of Rheumatology (ACR) criteria in patients with PsA treated with etanercept or placebo. ACR 20, 50, and 70 responses are defined as ≥20%, ≥50%, and ≥70% reductions, respectively, ...

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...